[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tb-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tb-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":14,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642208","phase-1-a-phase-i-study-of-lipovaxin-tuberculosis-vaccine-in-adult-healthy-populations-100642208",false,"NCT07647107","A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations","A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia","Inclusion Criteria\n\n1. Clinically Healthy participants aged 18-40 years;\n2. Participants have been informed properly regarding the study and signed the informed consent form.\n3. Participants will commit to comply with the instructions of the investigator and the schedule of the trial;\n4. Participants must have a negative IGRA and sputum.\n5. Clinically normal laboratory values for ureum, creatinine, SGOT, SGPT, complete blood count (CBC), urinalysis, coagulation test (PT, aPTT), total cholesterol, Globulin\u002FAlbumin ratio and CRP\n\nExclusion Criteria:\n\n1. Those who are currently diagnosed with tuberculosis or have a history of tuberculosis (positive IGRA or GenXpert sputum test or chest Xray suggestive of TB) and\u002For history of tuberculosis treatment; including TB Preventive Treatment (TPT);\n2. There are serious chronic diseases, or the disease is in the advanced stage that cannot be controlled smoothly, such as diabetes and thyroid disease;\n3. Currently suffering from or within 2 years of any of the following serious diseases, such as: advanced tumor, autoimmune disease, progressive atherosclerosis, acute exacerbation of the chronic obstructive pulmonary disease, acute or progressive liver or kidney disease, congestive heart failure, etc.; based on interview with participants\n4. Those with known or suspected (or high-risk) immune function impairments or abnormalities, such as those receiving more than 20mg\u002Fday of systemic glucocorticoids for 14 consecutive days within the last 4 weeks, immunosuppressants within 3 months, and Those who received protein preparations or blood products or plasma extracts outside the gastrointestinal tract within 3 months;\n5. People with allergic constitution, such as those with a history of allergy to two or more drugs or foods; a history of severe allergy to any component of the test vaccine, such as: anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenia Purpura, dyspnea, angioedema, etc.; or a history of the above-mentioned serious side effects after using any vaccine or drug in the past; history of bronchial asthma;\n6. Current patients with HIV antibody positive for human immunodeficiency virus;\n7. Women who are pregnant, breastfeeding, or have a positive urine pregnancy test during the screening period, or before vaccination, or who have childbearing plans during the study period;\n8. Subjects receive any vaccination within 1 month before and after dosing;\n9. Those who have participated in any other clinical research and used the investigational drug within 3 months before this clinical research;\n10. Any other situation that the researcher believes may affect the evaluation of the research.",true,"ALL","18 Years","40 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1",[27,28],"Tuberculosis","TB Infection",[30,27,31],"TB vaccine","Lipovaksin TB","NOT_YET_RECRUITING","2026-06-09",{"date":35,"type":36},"2026-06-15","ACTUAL",{"date":38,"type":22},"2026-08",{"date":40,"type":22},"2027-08",{"name":42,"class":43},"PT Bio Farma","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100632958","prevention-and-mass-screening-of-tb-in-prisons-in-paraguay-100632958","NCT07520448","Prevention and Mass Screening of TB in Prisons in Paraguay","Prevention and Mass Screening of TB in Prisons in Paraguay (PRESMAP-TB)","PRESMAP-TB","Inclusion Criteria:\n\n1. Be a person deprived of liberty (PDL) residing in one of the participating penitentiary centers during the study period.\n2. Be 18 years of age or older at the time of enrollment.\n3. Be present in the penitentiary facility at the time of a screening round or enter the facility during the study period.\n4. Provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Are currently undergoing treatment for active tuberculosis at the time of the screening round.\n2. Have a medical condition that, in the opinion of the clinical staff, prevents the safe performance of the planned diagnostic procedures.","MALE","65 Years",{"count":56,"type":22},4500,[58],"NA","The goal of this interventional study is to evaluate three tuberculosis (TB) screening and prevention strategies in prisons in Paraguay. The main questions it aims to answer are:\n\n* Which strategy is more effective for reducing the incidence rate of active TB?\n* Which strategy is more effective for reducing the TB infection rate?\n* Are these strategies safe, feasible, and cost-effective in prison settings?\n\nResearchers will compare three cluster-based, non-randomized programmatic strategies implemented in three prisons. These strategies differ in the frequency of screening, the diagnostic methods used, and the approach to tuberculosis preventive therapy (TPT).\n\nParticipants will:\n\n* undergo informed consent and clinical evaluation\n* receive TB screening through symptom assessment, chest digital X-ray with CAD, and rapid molecular testing, depending on site strategy\n* undergo IGRA testing and preventive therapy assessment, depending on the assigned strategy\n* be followed for 18 months, with screening rounds every 6 months or annually depending on the prison",[61,28,62,63],"Tuberculosis (TB)","Prisoners","Epidemiology","2026-04-08",{"date":66,"type":36},"2026-04-14",{"date":68,"type":22},"2026-08-01",{"date":70,"type":22},"2028-12-31",{"name":72,"class":73},"Universidad Nacional de Caaguazu","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100605609","parent-study-name-pulmonary-rehabilitation-to-reduce-post-tuberculosis-morbidity-tb-pure-100605609","NCT07164742","Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)","Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB PURE) A Randomized Multi-Centre Trial","TB Pure","Inclusion Criteria:\n\n* Age at least 18 years\n* Microbiologically confirmed (smear microscopy, GeneXpert or culture) pulmonary TB disease\\*\n* Not completed more than 2 weeks of TB treatment\n* Receiving TB care at the outpatient clinics at the TB PuRe study sites\n* Willingness to complete 48 weeks of study evaluations.\n* Access to a smartphone.\n\nExclusion Criteria:\n\n* Modified Medical Research Council score of 0 points (dyspnea only with strenuous exercise)\n* Multi or extensively drug-resistant TB disease\\*\n* Extrapulmonary TB disease at any clinical sites without pulmonary involvement\n* TB meningitis or TB of the spine\n* Symptomatic cardiovascular disease, including coronary artery disease, arrhythmias and congestive cardiac failure.\n* Karnofsky Score \\\u003C 40 points\n* Any medical condition that prevents pulmonary rehabilitation eg: fracture of lower\u002Fupper limbs\u002Fpregnancy\n* Bronchodilators and\u002For corticosteroids inhaled or otherwise.",{"count":83,"type":22},690,[58],"Individual-level, unblinded randomized controlled trial of an 8-week (short arm) or 24-week (extended arm) pulmonary rehabilitation program, relative to standard of care, to prevent post-tuberculosis respiratory morbidity. Randomization will occur in a 1:1:1 ratio at the initiation of treatment.",[87,88,28],"TB - Tuberculosis","TB",[90,91,92,93],"pulmonary tuberculosis","Pulmonary Rehabilitation","post-tuberculosis respiratory morbidity","Drug-sensitive TB","RECRUITING","2026-03-25",{"date":97,"type":36},"2026-03-27",{"date":99,"type":36},"2026-03-18",{"date":101,"type":22},"2028-09-15",{"name":103,"class":73},"Johns Hopkins University",2]